We are thrilled to announce that Empatica has partnered with Mobilise-D to integrate our validated Digital Mobility Outcomes (DMOs) into Empatica’s Health Monitoring Platform. This partnership signifies a major step forward in the use of digital endpoints for clinical care and research.
The Mobilise-D consortium, funded by the Innovative Medicines Initiative (IMI) and coordinated by Newcastle University and Novartis, has been at the forefront of developing novel methods to assess real-world mobility using digital technologies. Our collaboration with Empatica ensures that these advancements are now accessible to a broader audience, including those engaged in clinical trials and therapeutic development.
A Milestone in Digital Health
The Mobilise-D project was launched with the aim of revolutionizing the assessment of people’s mobility in their daily lives using digital measures and wearable sensors. The integration of the Mobilise-D DMOs in Empatica’s products and services ensures that the users of Empatica’s wearables have access to no less than 25 validated mobility outcomes. This integration addresses the growing demand for high-quality, purpose-specific measures and supports the dissemination of our innovative work within the healthcare industry. The partnership consolidates advanced mobility analytics with Empatica’s cutting-edge technology, providing a comprehensive solution for clinical care and research.
Addressing Barriers in Clinical Trials
Mobilise-D co-lead Lynn Rochester from Newcastle University, said: “A major barrier to the implementation of digital outcomes in clinical trials is the availability of systems that can deliver accurate and reliable data in a timely and seamless manner. We are delighted that Empatica has chosen to integrate the Mobilise-D advanced mobility analytics, addressing this barrier and moving digital outcome assessment closer to a sustainable solution that drives much-needed innovation and harmonization in clinical trials.”
Facilitating Clinical Care and Research
Our collaboration with Empatica not only simplifies the inclusion of Mobilise-D algorithms in pharma studies but also reduces patient and site burden. Mobilise-D is the first public program to systematically combine device considerations, analytical and clinical validation, and patient and regulatory engagement to generate reliable evidence for digital measures. The support from key pharmaceutical companies in developing these endpoints underscores the collaborative effort required to drive industry innovation.
Utilizing these algorithms in interventional clinical trial settings is a key step toward regulatory approval of digital endpoints in clinical drug development. We are excited about the potential this partnership holds for the future of digital health and precision medicine.
